Investing.com -- Barclays downgraded DexCom and Insulet, two large-cap diabetes device makers, to Underweight as it expects rising competition in 2026 and 2027 to weigh on valuation multiples and ...
DexCom, Inc. reduced its 2024 revenue guidance following a decline in new U.S. customers and revenue per customer, leading to a sharp share price drop, despite $750 million share buyback. DexCom faces ...
Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...
We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...
MARKHAM, Ontario--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback